ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO465

RAAS Inhibition Delays Onset of Nephrotic Syndrome due to TRPC6-Mediated FSGS: A Case Report of a Sibling Pair

Session Information

Category: Genetic Diseases of the Kidneys

  • 1202 Genetic Diseases of the Kidneys: Non-Cystic


  • Carver, Ashley W., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Glenn, Dorey A., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Westreich, Katherine D., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Transient receptor potential channel (TRPC6) is a slit diaphragm protein located on the podocyte, and a known genetic cause of focal segmental glomerulosclerosis (FSGS). Upregulation of TRPC6 channel activity is proposed to disturb podocyte structure, leading to proteinuria. ACE inhibitors (ACEi) demonstrate reno-protective benefits, reduction in proteinuria, and are commonly used to reduce proteinuria in FSGS. Here we describe progression to symptomatic nephrotic syndrome in a sibling pair with TRPC6 mediated steroid resistant FSGS as a function of early vs. late initiation of ACEi.

Case Description

Sibling A, the older of the two affected siblings, presented to care at 3 years of age with generalized edema, hypoalbuminemia (1.6g/dL), and nephrotic range proteinuria (UPCR 35mg/mg). Family history revealed that the child's father had end stage kidney disease of unclear etiology at the age of 3 years. Genetic testing of the child and parents demonstrated an autosomal dominant mutation in TRPC6 ((c.523C>T)[p.R175W]). Sibling A was unresponsive to steroids and cyclosporine and progressed to dialysis dependence due to fluid overload and pulmonary edema. Sibling A underwent kidney transplantation without recurrence of proteinuria. Sibling B, whose genetic diagnosis was made shortly after birth, was immediately started on RAAS inhibition, which was then maximally up-titrated (0.6mg/kg) as tolerated by blood pressure. He eventually underwent unilateral nephrectomy at age 4 to aid with proteinuria reduction. At age 5, nephrectomy of the remaining kidney was pursued with transition to peritoneal dialysis and preparation for kidney transplant. The age at dialysis dependence was 3 years in Sibling A and 5.5 years in Sibling B.


In summary, this report describes delay in progression to symptomatic nephrotic syndrome in a child with TRPC6 mutation due to early exposure to ACEi. The reno-protective mechanisms of ACEi are not fully understood and include proteinuria reduction and anti-fibrotic effects. Angiotensin II has been described to cause upregulation of TRPC6, thus aggressive blockade of this pathway may be a unique benefit to patients with TRPC6 mutations. A comparison of the siblings reported here would suggest that ACEi may significantly delay symptomatic nephrotic syndrome when started early and dosed maximally.